Adverum Biotechnologies Inc. (ADVM) shares are trading at higher $11.92 and the avg recommendation for the stock is Moderate Buy.
To add more color to this target, the company’s high over the last year is $26.98 and the low is $4.96. Over the last 52 weeks, ADVM is up 2.85% while the S&P 500 is up 13.97%. The catalyst for this interesting swing was the company’s recent earnings report.
A Notable Earnings Report
ADVM Return on Equity (ROE) is -37.70%, and its Return on Assets is -31.50%. All told, it is clear that, ADVM needs to be on your watchlist.
FREE CONFIDENTIAL REPORT
3 Stocks Set To Soar By January 1st, 2021
You have Successfully Subscribed!
Find out when ADVM reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
Of course, we must look beyond the financials and question how well those numbers represent the sustainable earnings power of the business. Investors need to know how sustainable this current run. ADVM has a short ratio of 9.30 and outstanding shares of 80.23M.
ADVM has seen increased volume after this news and investors are putting their support behind the value proposition. Traders will also note the company’s earnings per share came in at -1.22. Adverum Biotechnologies Inc. ADVM also noted assets of $331.18 million at the end of the last quarter. Investors should also keep an eye on sector updates as ADVM has historically followed its peers on positive news.
All told, Adverum Biotechnologies Inc. ADVM has strung together solid data and demonstrated underlying fundamentals. At its current valuation, ADVM represents an interesting risk/reward case. Traders should stay tuned to see if this recent report will push the stock to test recent resistance levels.
Adverum Biotechnologies Inc. ADVM is now commanding a market cap of 1.17B and a float of 55.83M. ADVM is increasing its credibility in this sector and that could lead to more upside down the line. Sign-up for continuing coverage on shares of ADVM stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in ADVM, either long or short, and we have not been compensated for this article.